Trial Profile
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs NBF 006 (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions; First in man
- Sponsors Nitto Biopharma
- 30 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Results (n=21) assessing the safety, tolerability, and PK of NBF-006 in patients with non-small cell lung, pancreatic, or colorectal cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 24 Apr 2023 Planned End Date changed from 1 Mar 2023 to 1 Aug 2024.